Drug Profile


Alternative Names: OB 5

Latest Information Update: 23 Jul 1998

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Anti-inflammatories; Antiasthmatics; Antivirals; Quinolizines
  • Mechanism of Action Immunomodulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma; Chronic hepatitis; Graft-versus-host disease; Hypersensitivity; Inflammation; Nephrotic syndrome

Most Recent Events

  • 23 Jul 1998 No-Development-Reported for Allergy in Japan (Unknown route)
  • 23 Jul 1998 No-Development-Reported for Nephrotic syndrome in Japan (Unknown route)
  • 23 Jul 1998 No-Development-Reported for Chronic hepatitis in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top